EPIQ Series Diagnostic Ultrasound System vs EchoNext
AI Verdict
Choose EPIQ Series Diagnostic Ultrasound System if…
Choose the Philips EPIQ Series Diagnostic Ultrasound System if your practice requires premium, AI-powered imaging across diverse clinical applications, including cardiology, OB/GYN, and radiology. This system excels in delivering high-resolution 2D, 3D/4D, and elastography imaging with advanced features like nSIGHT and PureWave technologies for enhanced diagnostic confidence and workflow efficiency.
View EPIQ Series Diagnostic Ultrasound System →Choose EchoNext if…
Choose EchoNext if your primary need is an affordable, non-invasive AI-powered screening tool to detect hidden structural heart disease from standard ECGs in a broad patient population. This tool is ideal for identifying patients at risk for conditions like heart failure, valve disease, and pulmonary hypertension, who may then require further diagnostic evaluation with an echocardiogram.
View EchoNext →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | EPIQ Series Diagnostic Ultrasound System | EchoNext |
|---|---|---|
| Pricing | Paid/enterprise | Starts at $600/month |
| Deployment | On premise | Available through the OpenEvidence clinical decision support platform. |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Yes AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
EPIQ Series Diagnostic Ultrasound SystemPhilips EPIQ Series is designed with an intuitive user interface, ergonomic features, and AI-enhanced workflows that aim to reduce button pushes and training time, making it easier for sonographers to use and improving overall workflow efficiency. EchoNext, while integrated into the OpenEvidence platform, is primarily an analytical tool, and its usability would largely depend on the interface of the platform it's deployed on.
Clinical Value
EchoNextEchoNext demonstrates superior clinical value by accurately detecting hidden structural heart disease from standard ECGs, outperforming cardiologists in diagnostic accuracy and enabling earlier intervention for conditions that often go undiagnosed. The Philips EPIQ Series offers advanced imaging and AI-powered measurements for enhanced diagnostic confidence across various applications, but EchoNext's ability to identify previously undetectable conditions from a routine, inexpensive test represents a more significant clinical breakthrough.
Pricing & Value
EchoNextEchoNext offers tiered subscription pricing starting at $600/month, making it a more accessible and transparent option, especially for smaller practices. The Philips EPIQ Series, as a premium ultrasound system, has an enterprise-level negotiated price for new systems, with refurbished units ranging from approximately $12,000 to $59,000, representing a significantly higher upfront investment.
Enterprise Readiness
EPIQ Series Diagnostic Ultrasound SystemThe Philips EPIQ Series is a comprehensive diagnostic ultrasound system designed for deployment in various clinical environments, from solo practices to large health systems, with established support and documentation. EchoNext is available through the OpenEvidence clinical decision support platform, which is used by a large number of U.S. physicians, indicating good integration potential, but the overall enterprise readiness would also depend on the scalability and support infrastructure of OpenEvidence.
Innovation
EchoNextEchoNext represents a significant innovation by utilizing AI to detect hidden structural heart disease from standard ECGs, a capability previously not thought possible with ECGs alone. This allows for early screening and intervention for conditions that often go undiagnosed. While the Philips EPIQ Series incorporates advanced AI for imaging and workflow, it enhances existing ultrasound capabilities rather than introducing a fundamentally new diagnostic paradigm.
Support & Docs
TieBoth tools are from established companies with a focus on healthcare. Philips, as a large medical device manufacturer, provides extensive documentation and technical support for its EPIQ Series. EchoNext, being deployed through the OpenEvidence platform, would likely leverage OpenEvidence's support structure, and its clinical validation has been well-documented in peer-reviewed studies. Without specific comparative details on response times, training programs, or documentation accessibility for both, it's difficult to definitively pick a winner.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | EPIQ Series Diagnostic Ultrasound System | EchoNext |
|---|---|---|
| Name | EPIQ Series Diagnostic Ultrasound System | EchoNext |
| Company | Philips Ultrasound | Pathway Labs |
| Description | The Philips EPIQ Series Diagnostic Ultrasound System offers premium AI-powered imaging and advanced workflow solutions for enhanced diagnostic confidence across diverse clinical applications. | EchoNext is an FDA-cleared AI tool from Pathway Labs that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension. |
| Target Size | Solo to large health systems | EchoNext is designed for broad access, from major hospitals to community practices. |
| Categories | Cardiology AI, OB/GYN AI, Radiology & Imaging AI | Cardiology AI, Clinical Decision Support & Reference, Lab & Diagnostics |
| Key Features | nSIGHT Imaging Architecture, PureWave Crystal Technology, xMATRIX Transducer Technology, Anatomical Intelligence Ultrasound (AIUS), AI-Enhanced Imaging & Automated Measurements, Elastography (Shear Wave & Strain), SmartExam & Real Time iSCAN (Autoscan), Flow Viewer & MicroFlow Imaging High Definition (MFI HD) | AI-powered ECG analysis, Detection of hidden structural heart disease, Identifies heart failure risk, Screens for valve disease, Detects pulmonary hypertension indicators, Utilizes standard 12-lead ECGs, FDA-cleared technology, Non-invasive diagnostic support |
Videos
Demos, reviews, and walkthroughs featuring EPIQ Series Diagnostic Ultrasound System and EchoNext.